Strattera Does Not Meaningfully Increase Serotonin
Strattera (atomoxetine) does not significantly increase serotonin levels at therapeutic doses—it is a selective norepinephrine reuptake inhibitor that primarily increases norepinephrine and dopamine in the prefrontal cortex, with minimal to no effect on serotonin. 1
Mechanism of Action
Atomoxetine functions as a selective norepinephrine reuptake inhibitor by binding to the norepinephrine transporter 1. The drug's selectivity profile demonstrates:
- High affinity for NET: Dissociation constant (Ki) of 5 nM
- Low affinity for SERT: Ki of 77 nM (15-fold less selective)
- Very low affinity for DAT: Ki of 1451 nM 2
In the prefrontal cortex specifically, atomoxetine increases both norepinephrine and dopamine approximately 3-fold, but does not alter serotonin levels 2. This dopamine effect occurs because norepinephrine transporters (not dopamine transporters) are responsible for dopamine reuptake in the prefrontal cortex, where dopamine transporters are scarce 1.
Clinical Evidence on Serotonin Effects
Multiple preclinical studies consistently demonstrate that atomoxetine at therapeutic doses:
- Does not increase serotonin in the prefrontal cortex 3, 2, 4
- Increases norepinephrine 3-fold and dopamine 3-fold, but leaves serotonin unchanged 2
- This pattern holds true for both acute and chronic administration 4
Important Clinical Caveat: Overdose Situations
While therapeutic doses do not affect serotonin, atomoxetine overdose can cause serotonin syndrome 5. A case report documented serotonin syndrome from 1200 mg atomoxetine ingestion (12 times the maximum daily dose), suggesting that at supratherapeutic concentrations, atomoxetine's weak serotonin reuptake inhibition becomes clinically relevant 5.
Additionally, one PET imaging study in primates suggested that at very high plasma concentrations (300-600 ng/mL, corresponding to 1.0-1.8 mg/kg doses), atomoxetine might occupy >85% of SERT 6. However, this finding has not been replicated in standard clinical use and contradicts multiple microdialysis studies showing no serotonin elevation.
Drug Interactions
The FDA label notes that SSRIs can elevate serum atomoxetine levels because atomoxetine is metabolized via CYP2D6, and some SSRIs inhibit this pathway 1, 7. This interaction is about atomoxetine metabolism, not additive serotonergic effects. Dose adjustment is recommended when combining atomoxetine with strong CYP2D6 inhibitors like paroxetine or fluoxetine 7.
Bottom Line for Clinical Practice
At standard therapeutic doses (up to 1.4 mg/kg/day or 100 mg/day maximum), atomoxetine functions as a selective norepinephrine reuptake inhibitor with secondary dopamine effects in the prefrontal cortex, but essentially zero serotonergic activity 1, 2, 4. The drug should not be considered to have meaningful serotonergic properties for treatment planning purposes.